HBI Biochip
Development of an intelligent microfluidic chip platform for applications in regenerative medicine and liquid biopsy
HBI Biochip is developing an intelligent, high-throughput microfluidic platform to enable the low-cost and efficient enrichment of cancer cells, bacteria, and other target cells from diverse biological samples such as blood, sputum, and urine. As the incidence of cancer and other diseases continues to rise, this technology supports earlier detection, improved prognoses, and more personalized treatment strategies. Designed for regenerative medicine and liquid biopsy, the platform enables personalized diagnostics and treatments for cancer, bacterial infections, and cardiovascular diseases.
Team member(s)
Mr Zhang Linghan* (PhD, Department of Biomedical Engineering, City University of Hong Kong)
Dr Zou Shangjie (Alumnus, Department of Biomedical Engineering, City University of Hong Kong)
Mr Xie Yuxiao (ResAsst, Department of Biomedical Engineering, City University of Hong Kong)
* Person-in-charge
(Info based on the team's application form)
Dr Zou Shangjie (Alumnus, Department of Biomedical Engineering, City University of Hong Kong)
Mr Xie Yuxiao (ResAsst, Department of Biomedical Engineering, City University of Hong Kong)
* Person-in-charge
(Info based on the team's application form)
Achievement(s)
- CityU HK Tech 300 Seed Fund (2024)
- 2024 ASMPT Technology Award (Nomination award)